Related Experiment Video
Updated: Jun 24, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer
Valérie Fonteyne1, Geert Villeirs, Nicolaas Lumen
1Department of Radiotherapy, Ghent University Hospital, Belgium. valerie.fonteyne@uzgent.be
Background And Purpose:
Urinary toxicity plays a major role in the quality of life (QOL) of patients treated with external beam radiotherapy as primary therapy for prostate cancer. In this study we report on: (1) Incidence of acute and late GU toxicity after intensity modulated radiotherapy (IMRT) for prostate cancer at Ghent University Hospital (GUH). (2) Time evolution of pre-IMRT and IMRT-induced acute and late GU toxicity.
Materials And Methods:
At GUH, 260 patients with a follow-up of > or = 12 months were treated with IMRT for prostate cancer. The incidence and evolution of GU toxicity were recorded.
Results:
Acute grades 3, 2 and 1 GU toxicity occurred in 8%, 42% and 42% of the patients, respectively. Late grades 3, 2 and 1 GU toxicity occurred in 3%, 19% and 40% of the patients, respectively. During therapy baseline grade 1 symptoms increased into grade 2 acute GU toxicity in 48%. After 1 and 2 years, 60% and 70% of the patients, respectively, had less GU symptoms when compared to the pre-treatment status.
Conclusion:
IMRT induces mild GU toxicity. There is an improvement in pre-IMRT obstructive miction disorders.
Related Concept Videos
Nursing Assessment of the Genitourinary System I: Health History
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Toxicity: Dose-Dependent Reactions
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management
